News
IRWD
--
0.00%
--
Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study
Zacks.com · 2d ago
Top Pharmaceutical Stocks for Q4 2021
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2021.
Investopedia · 4d ago
Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy
Zacks.com · 09/08 15:34
Horizon (HZNP) Begins Phase IV Study on Tepezza for Chronic TED
Zacks.com · 09/08 14:37
RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis
Zacks.com · 09/08 14:29
Irritable Bowel Syndrome Drugs Market: Expected CAGR, Top Manufacturers and Consumer Analysis across the Region and Globe, Opportunities and Growth till 2029
Research Nester published a report titled which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.
AmericaNewsHour · 09/08 06:26
Bayer's (BAYRY) Chronic Cough Candidate Meets Efficacy Goal
Zacks.com · 09/07 15:09
Takeda (TAK) Hematology Candidate Fails in Late-Stage Study
Zacks.com · 09/03 14:10
Irritable Bowel Syndrome Drugs Market- Up-To-Date Statistics, Development Areas And Emerging Opportunities Worldwide 2029
Research Nester published a report titled which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.
AmericaNewsHour · 09/03 13:51
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
BOSTON, September 02, 2021--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will participate in fireside chats at two upcoming virtual investor conferences in September:
Business Wire · 09/02 11:30
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
Zacks.com · 09/01 15:23
Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study
Zacks.com · 08/31 15:08
Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study
Zacks.com · 08/26 15:04
BRIEF-Ironwood Pharmaceuticals Reports FDA Approval Of Revised Linzess Label
reuters.com · 08/26 11:11
Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS Label
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS® (linaclotide) based on
Benzinga · 08/26 11:01
Ironwood Pharmaceuticals Gets FDA Approval for Revised Linzess Label
MT Newswires · 08/26 08:10
Fibrogen (FGEN)/Astellas Get EU Nod for Roxadustat for Anemia
Zacks.com · 08/20 15:42
Opioid Induced Constipation (OIC) Drugs Market Research Report with Size, Share, Value, CAGR, Outlook, Analysis, Latest Updates, Data, and News 2020-2026
Report Published by Introspective Market Research on Opioid Induced Constipation (OIC) Drugs Market provides detailed description about the collaborations, deals, designations, patent information etc. The report also provides detailed description of the co...
Heraldkeepers · 08/17 20:40
Jazz's (JAZZ) Xywav Gets FDA Nod for Idiopathic Hypersomnia
Zacks.com · 08/13 13:48
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
Webull provides a variety of real-time IRWD stock news. You can receive the latest news about Ironwood Pharms through multiple platforms. This information may help you make smarter investment decisions.
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).